The therapeutic efficacy of ethopropazine can be decreased when used in combination with rivastigmine.


The therapeutic efficacy of Linagliptin can be decreased when used in combination with Pipotiazine.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with Loxoprofen.


The therapeutic efficacy of codeine can be decreased when used in combination with amiodarone.


The therapeutic efficacy of PERHEXILINE can be decreased when used in combination with CALCIUM CHLORIDE.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with Naftifine.


The therapeutic efficacy of methyclothiazide can be decreased when used in combination with Pimecrolimus.


The therapeutic efficacy of nadolol can be decreased when used in combination with acemetacin.


The therapeutic efficacy of trichlormethiazide can be decreased when used in combination with flurbiprofen.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with Paliperidone.


The therapeutic efficacy of citric acid can be decreased when used in combination with DESOGESTREL.


The therapeutic efficacy of acarbose can be decreased when used in combination with olanzapine.


The therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole.


The therapeutic efficacy of Dienogest can be decreased when used in combination with thiamylal.


The therapeutic efficacy of rosiglitazone can be decreased when used in combination with Aripiprazole.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with Milnacipran.


The therapeutic efficacy of metformin can be decreased when used in combination with Paliperidone.


The therapeutic efficacy of Latanoprostene BUNOD can be decreased when used in combination with CLONIXIN.


The therapeutic efficacy of Drospirenone can be decreased when used in combination with thiamylal.


The therapeutic efficacy of felodipine can be decreased when used in combination with CALCIUM GLUCONATE.


The therapeutic efficacy of tolfenamic acid can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of Tafluprost can be decreased when used in combination with Propacetamol.


The therapeutic efficacy of latanoprost can be decreased when used in combination with tiaprofenic acid.


The therapeutic efficacy of alprostadil can be decreased when used in combination with Droxicam.


The therapeutic efficacy of ethotoin can be decreased when used in combination with Pregabalin.


The therapeutic efficacy of hydroflumethiazide can be decreased when used in combination with Droxicam.


The therapeutic efficacy of phenindione can be decreased when used in combination with MEGESTROL ACETATE.


The therapeutic efficacy of clopidogrel can be decreased when used in combination with Pregabalin.


The therapeutic efficacy of Latanoprostene BUNOD can be decreased when used in combination with Nepafenac.


The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with malathion.


The therapeutic efficacy of acemetacin can be decreased when used in combination with norepinephrine.


The therapeutic efficacy of Bimatoprost can be decreased when used in combination with floctafenine.


The therapeutic efficacy of hyoscyamine can be decreased when used in combination with malathion.


The therapeutic efficacy of Bivalirudin can be decreased when used in combination with progesterone.


The therapeutic efficacy of voglibose can be decreased when used in combination with olanzapine.


The therapeutic efficacy of DEXMEDETOMIDINE can be decreased when used in combination with mianserin.


The therapeutic efficacy of Vildagliptin can be decreased when used in combination with olanzapine.


The therapeutic efficacy of gemeprost can be decreased when used in combination with Nepafenac.


The therapeutic efficacy of glimepiride can be decreased when used in combination with risperidone.


The therapeutic efficacy of clarithromycin can be decreased when used in combination with lisinopril.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with cefmetazole.


The therapeutic efficacy of argatroban can be decreased when used in combination with ETONOGESTREL.


The therapeutic efficacy of lorazepam can be decreased when used in combination with mianserin.


The therapeutic efficacy of tolazamide can be decreased when used in combination with Torasemide.


The therapeutic efficacy of Ibandronic Acid can be decreased when used in combination with Esomeprazole.


The therapeutic efficacy of dinoprost tromethamine can be decreased when used in combination with Teriflunomide.


The therapeutic efficacy of chenodeoxycholic acid can be decreased when used in combination with tibolone.


The therapeutic efficacy of gliclazide can be decreased when used in combination with Torasemide.


The therapeutic efficacy of Trospium can be decreased when used in combination with Echothiophate.


The therapeutic efficacy of Limaprost can be decreased when used in combination with sulindac.


The therapeutic efficacy of estramustine can be decreased when used in combination with phenytoin.


The therapeutic efficacy of indapamide can be decreased when used in combination with SERATRODAST.


The therapeutic efficacy of ANISOTROPINE METHYLBROMIDE can be decreased when used in combination with pyridostigmine.


The therapeutic efficacy of Gliquidone can be decreased when used in combination with Pasireotide.


The therapeutic efficacy of pancuronium can be decreased when used in combination with malathion.


The therapeutic efficacy of PHENYLACETIC ACID can be decreased when used in combination with dexamethasone.


The therapeutic efficacy of equilin can be decreased when used in combination with mifepristone.


The therapeutic efficacy of Corticorelin ovine can be decreased when used in combination with diflorasone.


The therapeutic efficacy of metformin can be decreased when used in combination with Dienogest.


The therapeutic efficacy of PIPECURONIUM can be decreased when used in combination with malathion.


The therapeutic efficacy of Vecuronium can be decreased when used in combination with malathion.


The therapeutic efficacy of Empagliflozin can be decreased when used in combination with nicotinic acid.


The therapeutic efficacy of dinoprost tromethamine can be decreased when used in combination with Salsalate.


The therapeutic efficacy of glipizide can be decreased when used in combination with Dienogest.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with CYPROTERONE ACETATE.


The therapeutic efficacy of folic acid can be decreased when used in combination with diflunisal.


The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Isoflurophate.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Avibactam.


The therapeutic efficacy of chlorthalidone can be decreased when used in combination with BENZYDAMINE.


The therapeutic efficacy of gliclazide can be decreased when used in combination with dexamethasone.


The therapeutic efficacy of indapamide can be decreased when used in combination with ketoprofen.


The therapeutic efficacy of indapamide can be decreased when used in combination with Nepafenac.


The therapeutic efficacy of Atracurium besylate can be decreased when used in combination with malathion.


The therapeutic efficacy of Pioglitazone can be decreased when used in combination with rapamycin.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with mefenamic acid.


The therapeutic efficacy of Fondaparinux can be decreased when used in combination with MEDROGESTONE.


The therapeutic efficacy of L-thyroxine can be decreased when used in combination with Levomilnacipran.


The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Pipotiazine.


The therapeutic efficacy of glyburide can be decreased when used in combination with risperidone.


The therapeutic efficacy of misoprostol can be decreased when used in combination with azelastine.


The therapeutic efficacy of GLYCEROL PHENYLBUTYRATE can be decreased when used in combination with Tixocortol.


The therapeutic efficacy of dicumarol can be decreased when used in combination with norethindrone.


The therapeutic efficacy of glimepiride can be decreased when used in combination with estradiol.


The therapeutic efficacy of Linagliptin can be decreased when used in combination with prednisone.


The therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.


The therapeutic efficacy of PIPECURONIUM can be decreased when used in combination with Echothiophate.


The therapeutic efficacy of ouabain can be decreased when used in combination with Eplerenone.


The therapeutic efficacy of pancuronium can be decreased when used in combination with Echothiophate.


The therapeutic efficacy of carboprost trometamol can be decreased when used in combination with Droxicam.


The therapeutic efficacy of Empagliflozin can be decreased when used in combination with TRIPTORELIN.


The therapeutic efficacy of metolazone can be decreased when used in combination with meclofenamic acid.


The therapeutic efficacy of Fondaparinux can be decreased when used in combination with dydrogesterone.


The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Asenapine.


The therapeutic efficacy of cyclopentolate can be decreased when used in combination with decamethonium.


The therapeutic efficacy of cinnarizine can be decreased when used in combination with Calcium acetate.


The therapeutic efficacy of nitrendipine can be decreased when used in combination with acemetacin.


The therapeutic efficacy of PIPECURONIUM can be decreased when used in combination with memantine.


The therapeutic efficacy of Miglustat can be decreased when used in combination with trichlormethiazide.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with polythiazide.


The therapeutic efficacy of rosiglitazone can be decreased when used in combination with trichlormethiazide.


The therapeutic efficacy of EDTA can be decreased when used in combination with DESOGESTREL.


The therapeutic efficacy of Limaprost can be decreased when used in combination with Propacetamol.


The therapeutic efficacy of chenodeoxycholic acid can be decreased when used in combination with estrone.


The therapeutic efficacy of glimepiride can be decreased when used in combination with TRIPTORELIN.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with Torasemide.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with CLONIXIN.


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with carprofen.


The therapeutic efficacy of Tramadol can be decreased when used in combination with Lorcaserin.


The therapeutic efficacy of glipizide can be decreased when used in combination with nicotinic acid.


The therapeutic efficacy of metformin can be decreased when used in combination with nelfinavir.


The therapeutic efficacy of ETHYNODIOL DIACETATE can be decreased when used in combination with Mephobarbital.


The therapeutic efficacy of DESOGESTREL can be decreased when used in combination with METHOHEXITAL.


The therapeutic efficacy of tolbutamide can be decreased when used in combination with Lurasidone.


The therapeutic efficacy of gliclazide can be decreased when used in combination with Lurasidone.


The therapeutic efficacy of warfarin can be decreased when used in combination with allylestrenol.


The therapeutic efficacy of MOXONIDINE can be decreased when used in combination with amitriptyline.


The therapeutic efficacy of ethopropazine can be decreased when used in combination with physostigmine.


The therapeutic efficacy of dinoprost tromethamine can be decreased when used in combination with tenoxicam.


The therapeutic efficacy of Tafluprost can be decreased when used in combination with tolmetin.


The therapeutic efficacy of BECLOMETHASONE DIPROPIONATE can be decreased when used in combination with amoxapine.


The therapeutic efficacy of Canagliflozin can be decreased when used in combination with goserelin.


The therapeutic efficacy of Unoprostone can be decreased when used in combination with Pimecrolimus.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with amoxapine.


The therapeutic efficacy of Saxagliptin can be decreased when used in combination with ETONOGESTREL.


The therapeutic efficacy of benzoic acid can be decreased when used in combination with halcinonide.


The therapeutic efficacy of epoprostenol can be decreased when used in combination with antipyrine.


The therapeutic efficacy of Latanoprostene BUNOD can be decreased when used in combination with Propacetamol.


The therapeutic efficacy of dinoprost tromethamine can be decreased when used in combination with Naftifine.


The therapeutic efficacy of dienestrol can be decreased when used in combination with carbamazepine.


The therapeutic efficacy of Limaprost can be decreased when used in combination with Naftifine.


The therapeutic efficacy of tolazamide can be decreased when used in combination with hydrochlorothiazide.


The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Isotretinoin.


The therapeutic efficacy of ursodiol can be decreased when used in combination with gemfibrozil.


The therapeutic efficacy of chlorothiazide can be decreased when used in combination with BENZYDAMINE.


The therapeutic efficacy of CYSTEAMINE can be decreased when used in combination with nizatidine.


The therapeutic efficacy of MIGLITOL can be decreased when used in combination with CORTISONE ACETATE.


The therapeutic efficacy of liothyronine can be decreased when used in combination with paroxetine.


The therapeutic efficacy of Vildagliptin can be decreased when used in combination with SAQUINAVIR.


The therapeutic efficacy of folic acid can be decreased when used in combination with Etoricoxib.


The therapeutic efficacy of hydrochlorothiazide can be decreased when used in combination with Olopatadine.


The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Medroxyprogesterone acetate.


The therapeutic efficacy of Dienogest can be decreased when used in combination with thiopental.


The therapeutic efficacy of Sitagliptin can be decreased when used in combination with norethindrone.


The therapeutic efficacy of trichlormethiazide can be decreased when used in combination with suprofen.


The therapeutic efficacy of GLYCEROL PHENYLBUTYRATE can be decreased when used in combination with paramethasone.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with RIFAPENTINE.


The therapeutic efficacy of betahistine can be decreased when used in combination with clemastine.


The therapeutic efficacy of bepridil can be decreased when used in combination with CALCIUM CHLORIDE.


The therapeutic efficacy of calcitriol can be decreased when used in combination with Mometasone.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with clenbuterol.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with rapamycin.


The therapeutic efficacy of Pinaverium can be decreased when used in combination with CALCIUM CHLORIDE.


The therapeutic efficacy of chlorthalidone can be decreased when used in combination with azelastine.


The therapeutic efficacy of methenamine can be decreased when used in combination with MAGNESIUM OXIDE.


The therapeutic efficacy of Saxagliptin can be decreased when used in combination with BENDROFLUMETHIAZIDE.


The therapeutic efficacy of flunisolide can be decreased when used in combination with amoxapine.


The therapeutic efficacy of ALENDRONIC ACID can be decreased when used in combination with lansoprazole.


The therapeutic efficacy of Limaprost can be decreased when used in combination with Olsalazine.


The therapeutic efficacy of pramipexole can be decreased when used in combination with Cariprazine.


The therapeutic efficacy of Empagliflozin can be decreased when used in combination with pentamidine.


The therapeutic efficacy of Miglustat can be decreased when used in combination with HYDROXYPROGESTERONE CAPROATE.


The therapeutic efficacy of Empagliflozin can be decreased when used in combination with NORGESTIMATE.


The therapeutic efficacy of Tramadol can be decreased when used in combination with ritonavir.


The therapeutic efficacy of BENDROFLUMETHIAZIDE can be decreased when used in combination with Droxicam.


The therapeutic efficacy of Tramadol can be decreased when used in combination with nicardipine.


The therapeutic efficacy of midazolam can be decreased when used in combination with Yohimbine.


The therapeutic efficacy of CYSTEAMINE can be decreased when used in combination with Aluminium hydroxide.


The therapeutic efficacy of MIGLITOL can be decreased when used in combination with indinavir.


The therapeutic efficacy of oxyphenonium can be decreased when used in combination with malathion.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with paromomycin.


The therapeutic efficacy of Unoprostone can be decreased when used in combination with resveratrol.


The therapeutic efficacy of acetyldigitoxin can be decreased when used in combination with triamterene.


The therapeutic efficacy of felodipine can be decreased when used in combination with Calcium phosphate.


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with indomethacin.


The therapeutic efficacy of glipizide can be decreased when used in combination with bumetanide.


The therapeutic efficacy of Corticorelin ovine can be decreased when used in combination with Dehydroepiandrosterone.


The therapeutic efficacy of misoprostol can be decreased when used in combination with oxaprozin.


The therapeutic efficacy of Camazepam can be decreased when used in combination with Yohimbine.


The therapeutic efficacy of EDTA can be decreased when used in combination with allylestrenol.


The therapeutic efficacy of nateglinide can be decreased when used in combination with ETONOGESTREL.


The therapeutic efficacy of Limaprost can be decreased when used in combination with BENZYDAMINE.


The therapeutic efficacy of acarbose can be decreased when used in combination with indapamide.


The therapeutic efficacy of meprobamate can be decreased when used in combination with mianserin.


The therapeutic efficacy of PENICILLIN G PROCAINE can be decreased when used in combination with Tigecycline.


The therapeutic efficacy of metformin can be decreased when used in combination with ETHACRYNIC ACID.


The therapeutic efficacy of Repaglinide can be decreased when used in combination with piperazine.


The therapeutic efficacy of triazolam can be decreased when used in combination with Yohimbine.


The therapeutic efficacy of MIGLITOL can be decreased when used in combination with Levomepromazine.


The therapeutic efficacy of gemeprost can be decreased when used in combination with salicylamide.


The therapeutic efficacy of Ximelagatran can be decreased when used in combination with MEDROGESTONE.


The therapeutic efficacy of cyclopentolate can be decreased when used in combination with mefloquine.


The therapeutic efficacy of rosiglitazone can be decreased when used in combination with Asenapine.


The therapeutic efficacy of ipratropium can be decreased when used in combination with ambenonium.


The therapeutic efficacy of Miglustat can be decreased when used in combination with Asenapine.


The therapeutic efficacy of GALLAMINE TRIETHIODIDE can be decreased when used in combination with ambenonium.


The therapeutic efficacy of acarbose can be decreased when used in combination with Nilotinib.


The therapeutic efficacy of Zoledronic acid can be decreased when used in combination with rabeprazole.


The therapeutic efficacy of chlorothiazide can be decreased when used in combination with tiaprofenic acid.


The therapeutic efficacy of tolazamide can be decreased when used in combination with betamethasone.


The therapeutic efficacy of methyclothiazide can be decreased when used in combination with carprofen.


The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with ambenonium.


The therapeutic efficacy of Saxagliptin can be decreased when used in combination with HYDROXYPROGESTERONE CAPROATE.


The therapeutic efficacy of hydromorphone can be decreased when used in combination with naltrexone.


The therapeutic efficacy of Tixocortol can be decreased when used in combination with mifepristone.


The therapeutic efficacy of stavudine can be decreased when used in combination with doxorubicin.


The therapeutic efficacy of Gliquidone can be decreased when used in combination with polythiazide.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with Asenapine.


The therapeutic efficacy of misoprostol can be decreased when used in combination with Propacetamol.


The therapeutic efficacy of Travoprost can be decreased when used in combination with Propacetamol.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with Levonorgestrel.


The therapeutic efficacy of metolazone can be decreased when used in combination with nimesulide.


The therapeutic efficacy of QUINETHAZONE can be decreased when used in combination with chloroquine.


The therapeutic efficacy of polythiazide can be decreased when used in combination with chloroquine.


The therapeutic efficacy of procyclidine can be decreased when used in combination with NEOSTIGMINE.


The therapeutic efficacy of digitoxin can be decreased when used in combination with triamterene.


The therapeutic efficacy of betahistine can be decreased when used in combination with cimetidine.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with phenylpropanolamine.


The therapeutic efficacy of ethopropazine can be decreased when used in combination with mefloquine.


The therapeutic efficacy of calcitriol can be decreased when used in combination with FLUOCINOLONE ACETONIDE.


The therapeutic efficacy of ETONOGESTREL can be decreased when used in combination with Ulipristal.


The therapeutic efficacy of mecamylamine can be decreased when used in combination with NEOSTIGMINE.


The therapeutic efficacy of ILOPROST can be decreased when used in combination with ketoprofen.


The therapeutic efficacy of hydrochlorothiazide can be decreased when used in combination with Salsalate.


The therapeutic efficacy of amphotericin b can be decreased when used in combination with Naftifine.


The therapeutic efficacy of eperisone can be decreased when used in combination with Pregabalin.


The therapeutic efficacy of QUINETHAZONE can be decreased when used in combination with sulfasalazine.


The therapeutic efficacy of Saxagliptin can be decreased when used in combination with methylprednisolone.


The therapeutic efficacy of Ximelagatran can be decreased when used in combination with progesterone.


The therapeutic efficacy of Latanoprostene BUNOD can be decreased when used in combination with meclofenamic acid.


The therapeutic efficacy of Prostaglandin E2 can be decreased when used in combination with mesalamine.


The therapeutic efficacy of liothyronine can be decreased when used in combination with estriol.


The therapeutic efficacy of polythiazide can be decreased when used in combination with tiaprofenic acid.


The therapeutic efficacy of MIGLITOL can be decreased when used in combination with Medroxyprogesterone acetate.


The therapeutic efficacy of QUINETHAZONE can be decreased when used in combination with tiaprofenic acid.


The therapeutic efficacy of chlorthalidone can be decreased when used in combination with meclofenamic acid.


The therapeutic efficacy of hyoscyamine can be decreased when used in combination with Isoflurophate.


The therapeutic efficacy of Unoprostone can be decreased when used in combination with Etoricoxib.


The therapeutic efficacy of QUINETHAZONE can be decreased when used in combination with resveratrol.


The therapeutic efficacy of mesalamine can be decreased when used in combination with SODIUM BICARBONATE.


The therapeutic efficacy of ILOPROST can be decreased when used in combination with Naftifine.


The therapeutic efficacy of glyburide can be decreased when used in combination with quetiapine.


The therapeutic efficacy of nimodipine can be decreased when used in combination with CALCIUM GLUCONATE.


The therapeutic efficacy of ILOPROST can be decreased when used in combination with Choline magnesium trisalicylate.


The therapeutic efficacy of PERINDOPRIL can be decreased when used in combination with acemetacin.


The therapeutic efficacy of tolazoline can be decreased when used in combination with acemetacin.


The therapeutic efficacy of Candesartan cilexetil can be decreased when used in combination with acemetacin.


The therapeutic efficacy of hydrochlorothiazide can be decreased when used in combination with meclofenamic acid.


The therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of Drospirenone can be decreased when used in combination with Hexobarbital.


The therapeutic efficacy of latanoprost can be decreased when used in combination with floctafenine.


The therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of cilnidipine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of chlorthalidone can be decreased when used in combination with Lornoxicam.


The therapeutic efficacy of Fondaparinux can be decreased when used in combination with Nomegestrol.


The therapeutic efficacy of manidipine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of BENDROFLUMETHIAZIDE can be decreased when used in combination with zaltoprofen.


The therapeutic efficacy of metolazone can be decreased when used in combination with Etoricoxib.


The therapeutic efficacy of estradiol can be decreased when used in combination with Mephobarbital.


The therapeutic efficacy of OXCARBAZEPINE can be decreased when used in combination with Pregabalin.


The therapeutic efficacy of Etidronic acid can be decreased when used in combination with rabeprazole.


The therapeutic efficacy of clonidine can be decreased when used in combination with mianserin.


The therapeutic efficacy of dinoprost tromethamine can be decreased when used in combination with sulfasalazine.


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Loxoprofen.


The therapeutic efficacy of Gatate can be decreased when used in combination with Vapreotide.


The therapeutic efficacy of Linagliptin can be decreased when used in combination with HYDROXYPROGESTERONE CAPROATE.


The therapeutic efficacy of glipizide can be decreased when used in combination with tacrolimus.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with trichlormethiazide.


The therapeutic efficacy of tolazamide can be decreased when used in combination with dexamethasone.


The therapeutic efficacy of rosiglitazone can be decreased when used in combination with Estrone sulfate.


The therapeutic efficacy of Miglustat can be decreased when used in combination with Estrone sulfate.


The therapeutic efficacy of Gliquidone can be decreased when used in combination with methylprednisolone.


The therapeutic efficacy of TRIMETHAPHAN can be decreased when used in combination with pyridostigmine.


The therapeutic efficacy of PARAMETHADIONE can be decreased when used in combination with mianserin.


The therapeutic efficacy of diethylstilbestrol can be decreased when used in combination with Mephobarbital.


The therapeutic efficacy of mitotane can be decreased when used in combination with spironolactone.


The therapeutic efficacy of Unoprostone can be decreased when used in combination with mesalamine.


The therapeutic efficacy of metolazone can be decreased when used in combination with suprofen.


The therapeutic efficacy of Bimatoprost can be decreased when used in combination with mycophenolic acid.


The therapeutic efficacy of Limaprost can be decreased when used in combination with Droxicam.


The therapeutic efficacy of GLYCEROL PHENYLBUTYRATE can be decreased when used in combination with Fluprednidene.


The therapeutic efficacy of Canagliflozin can be decreased when used in combination with danazol.


The therapeutic efficacy of Travoprost can be decreased when used in combination with salicylamide.


The therapeutic efficacy of felodipine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of glipizide can be decreased when used in combination with chlorthalidone.


The therapeutic efficacy of Gliquidone can be decreased when used in combination with Fosamprenavir.


The therapeutic efficacy of Travoprost can be decreased when used in combination with BALSALAZIDE.


The therapeutic efficacy of Iobenguane can be decreased when used in combination with xylometazoline.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with arsenic trioxide.


The therapeutic efficacy of oxybutynin can be decreased when used in combination with memantine.


The therapeutic efficacy of MIGLITOL can be decreased when used in combination with Darunavir.


The therapeutic efficacy of tolbutamide can be decreased when used in combination with dexamethasone.


The therapeutic efficacy of codeine can be decreased when used in combination with Lopinavir.


The therapeutic efficacy of CYSTEAMINE can be decreased when used in combination with cimetidine.


The therapeutic efficacy of GLYCEROL PHENYLBUTYRATE can be decreased when used in combination with CLOCORTOLONE.


The therapeutic efficacy of Alogliptin can be decreased when used in combination with hydrochlorothiazide.


The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Choline magnesium trisalicylate.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with dapsone.


The therapeutic efficacy of Bismuth subcitrate potassium can be decreased when used in combination with CALCIUM CARBONATE.


The therapeutic efficacy of ATROPINE can be decreased when used in combination with pyridostigmine.


The therapeutic efficacy of calcitriol can be decreased when used in combination with betamethasone.


The therapeutic efficacy of fludiazepam can be decreased when used in combination with mianserin.


The therapeutic efficacy of Drospirenone can be decreased when used in combination with tretinoin.


The therapeutic efficacy of Sitagliptin can be decreased when used in combination with dexamethasone.


The therapeutic efficacy of 4-PHENYLBUTYRIC ACID can be decreased when used in combination with Estrone sulfate.


The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olsalazine.


The therapeutic efficacy of Ximelagatran can be decreased when used in combination with norethindrone.


The therapeutic efficacy of rosiglitazone can be decreased when used in combination with HYDROXYPROGESTERONE CAPROATE.


The therapeutic efficacy of acarbose can be decreased when used in combination with Iloperidone.


The therapeutic efficacy of mesalamine can be decreased when used in combination with doxepin.


The therapeutic efficacy of metolazone can be decreased when used in combination with Icatibant.


The therapeutic efficacy of tolbutamide can be decreased when used in combination with ETHACRYNIC ACID.


The therapeutic efficacy of 4-PHENYLBUTYRIC ACID can be decreased when used in combination with Clobetasone.


The therapeutic efficacy of carboprost trometamol can be decreased when used in combination with Magnesium salicylate.


The therapeutic efficacy of hydrochlorothiazide can be decreased when used in combination with mycophenolate mofetil.


The therapeutic efficacy of Limaprost can be decreased when used in combination with floctafenine.


The therapeutic efficacy of UMECLIDINIUM can be decreased when used in combination with metoclopramide.


The therapeutic efficacy of oxymorphone can be decreased when used in combination with naltrexone.


The therapeutic efficacy of Sitagliptin can be decreased when used in combination with BREXPIPRAZOLE.


The therapeutic efficacy of dobutamine can be decreased when used in combination with Calcium citrate.


The therapeutic efficacy of clarithromycin can be decreased when used in combination with Isoflurophate.


The therapeutic efficacy of codeine can be decreased when used in combination with methadone.


The therapeutic efficacy of ipratropium can be decreased when used in combination with memantine.


The therapeutic efficacy of chlorothiazide can be decreased when used in combination with antipyrine.


The therapeutic efficacy of cloxacillin can be decreased when used in combination with minocycline.


The therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with NEOSTIGMINE.


The therapeutic efficacy of Bivalirudin can be decreased when used in combination with GESTODENE.


The therapeutic efficacy of BENDROFLUMETHIAZIDE can be decreased when used in combination with mesalamine.


The therapeutic efficacy of nateglinide can be decreased when used in combination with Temsirolimus.


The therapeutic efficacy of Unoprostone can be decreased when used in combination with flurbiprofen.


The therapeutic efficacy of ILOPROST can be decreased when used in combination with mefenamic acid.


The therapeutic efficacy of PENTAERYTHRITOL TETRANITRATE can be decreased when used in combination with Medroxyprogesterone acetate.


The therapeutic efficacy of Empagliflozin can be decreased when used in combination with MEGESTROL ACETATE.


The therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Alitretinoin.


The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with ceftriaxone.


The therapeutic efficacy of tolazamide can be decreased when used in combination with DESOGESTREL.


The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Mephobarbital.


The therapeutic efficacy of Norelgestromin can be decreased when used in combination with amobarbital.


The therapeutic efficacy of chlorpropamide can be decreased when used in combination with Paliperidone.


The therapeutic efficacy of biperiden can be decreased when used in combination with galanthamine.


The therapeutic efficacy of Pivmecillinam can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of Pivampicillin can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of TICARCILLIN can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of Tazobactam can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of methicillin can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of bacampicillin can be decreased when used in combination with chlortetracycline.


The therapeutic efficacy of CYSTEAMINE can be decreased when used in combination with CALCIUM CARBONATE.


METHAMPHETAMINE may increase the hypertensive activities of Phenelzine.


Arformoterol may increase the hypertensive activities of cabergoline.


isoproterenol may increase the hypertensive activities of cabergoline.


metaproterenol may increase the hypertensive activities of cabergoline.


MEPHENTERMINE may increase the hypertensive activities of dihydroergotamine.


Lisdexamfetamine may increase the hypertensive activities of moclobemide.


dextroamphetamine may increase the hypertensive activities of pargyline.


clenbuterol may increase the hypertensive activities of ERGOTAMINE.


droxidopa may increase the hypertensive activities of methylergonovine.


doxapram may increase the hypertensive activities of procarbazine.


phenylpropanolamine may increase the hypertensive activities of dihydroergotamine.


phenylpropanolamine may increase the hypertensive activities of cabergoline.


Lisdexamfetamine may increase the hypertensive activities of Toloxatone.


dextroamphetamine may increase the hypertensive activities of furazolidone.


Lisdexamfetamine may increase the hypertensive activities of Pirlindole.


benzphetamine may increase the hypertensive activities of linezolid.


Amfepramone may increase the hypertensive activities of tranylcypromine.


metaraminol may increase the hypertensive activities of bromocriptine.


PSEUDOEPHEDRINE may increase the hypertensive activities of linezolid.


droxidopa may increase the hypertensive activities of rizatriptan.


droxidopa may increase the hypertensive activities of naratriptan.


hydroxyamphetamine may increase the hypertensive activities of Phenelzine.


norepinephrine may increase the hypertensive activities of bromocriptine.


Ephedrine may increase the hypertensive activities of bromocriptine.


metaraminol may increase the hypertensive activities of selegiline.


ATROPINE may increase the hypertensive activities of pargyline.


phenmetrazine may increase the hypertensive activities of Atomoxetine.


tizanidine may increase the hypertensive activities of ERGOTAMINE.


methylphenidate may increase the hypertensive activities of procarbazine.


ATROPINE may increase the hypertensive activities of furazolidone.


dextroamphetamine may increase the hypertensive activities of methylene blue.


benzphetamine may increase the hypertensive activities of Phenelzine.


PROCATEROL may increase the hypertensive activities of bromocriptine.


levonordefrin may increase the hypertensive activities of moclobemide.


metaraminol may increase the hypertensive activities of linezolid.


midodrine may increase the hypertensive activities of tranylcypromine.


METHAMPHETAMINE may increase the hypertensive activities of methylene blue.


METHAMPHETAMINE may increase the hypertensive activities of Pirlindole.


METHAMPHETAMINE may increase the hypertensive activities of Toloxatone.


ARBUTAMINE may increase the hypertensive activities of bromocriptine.


doxapram may increase the hypertensive activities of isocarboxazid.


ERGOTAMINE may increase the hypertensive activities of pargyline.


GUANFACINE may increase the hypertensive activities of ERGOTAMINE.


Salbutamol may increase the hypertensive activities of ERGOTAMINE.


MEPHENTERMINE may increase the hypertensive activities of cabergoline.


epinephrine may increase the hypertensive activities of AMPHETAMINE.


epinephrine may increase the hypertensive activities of procarbazine.


PROCATEROL may increase the hypertensive activities of cabergoline.


levonordefrin may increase the hypertensive activities of furazolidone.


Ephedrine may increase the hypertensive activities of methylergonovine.


levonordefrin may increase the hypertensive activities of tranylcypromine.


brimonidine may increase the hypertensive activities of dihydroergotamine.


nylidrin may increase the hypertensive activities of bromocriptine.


Arformoterol may increase the hypertensive activities of dihydroergotamine.


metaraminol may increase the hypertensive activities of dihydroergotamine.


halothane may increase the hypertensive activities of methylphenidate.


methylphenidate may increase the hypertensive activities of rasagiline.


isoetharine may increase the hypertensive activities of ERGOTAMINE.


tetrahydrozoline may increase the hypertensive activities of tranylcypromine.


Pirlindole may increase the hypertensive activities of tranylcypromine.


Dexmethylphenidate may increase the hypertensive activities of Pirlindole.


Dexmethylphenidate may increase the hypertensive activities of Toloxatone.


phenylephrine may increase the hypertensive activities of Phenelzine.


formoterol may increase the hypertensive activities of ERGOTAMINE.


furazolidone may increase the hypertensive activities of rasagiline.


OLODATEROL may increase the hypertensive activities of methylergonovine.


sevoflurane may increase the hypertensive activities of methylphenidate.


midodrine may increase the hypertensive activities of isocarboxazid.


Lofexidine may increase the hypertensive activities of ERGOTAMINE.


methyldopa may increase the hypertensive activities of cabergoline.


Salmeterol may increase the hypertensive activities of methylergonovine.


tetrahydrozoline may increase the hypertensive activities of Atomoxetine.


ERGOTAMINE may increase the hypertensive activities of furazolidone.


HEXOPRENALINE may increase the hypertensive activities of ERGOTAMINE.


MEPHENTERMINE may increase the hypertensive activities of tranylcypromine.


phenylephrine may increase the hypertensive activities of Atomoxetine.


epinastine may increase the hypertensive activities of methylergonovine.


metaraminol may increase the hypertensive activities of Phenelzine.


methoxamine may increase the hypertensive activities of pargyline.


MEPHENTERMINE may increase the hypertensive activities of furazolidone.


naphazoline may increase the hypertensive activities of methylergonovine.


terbutaline may increase the hypertensive activities of linezolid.


procarbazine may increase the hypertensive activities of furazolidone.


brimonidine may increase the hypertensive activities of methylergonovine.


tizanidine may increase the hypertensive activities of methylergonovine.


isoxsuprine may increase the hypertensive activities of ERGOTAMINE.


apraclonidine may increase the hypertensive activities of ERGOTAMINE.


norepinephrine may increase the hypertensive activities of cabergoline.


epinephrine may increase the hypertensive activities of cabergoline.


AMPHETAMINE may increase the hypertensive activities of Pirlindole.


droxidopa may increase the hypertensive activities of Frovatriptan.


dobutamine may increase the hypertensive activities of Tedizolid phosphate.


Salmeterol may increase the hypertensive activities of ERGOTAMINE.


nylidrin may increase the hypertensive activities of Tedizolid phosphate.


phenylephrine may increase the hypertensive activities of pargyline.


furazolidone may increase the hypertensive activities of Toloxatone.


furazolidone may increase the hypertensive activities of Pirlindole.


formoterol may increase the hypertensive activities of bromocriptine.


Salbutamol may increase the hypertensive activities of cabergoline.


droxidopa may increase the hypertensive activities of Ephedrine.


levonordefrin may increase the hypertensive activities of selegiline.


PIRBUTEROL may increase the hypertensive activities of bromocriptine.


dextroamphetamine may increase the hypertensive activities of moclobemide.


droxidopa may increase the hypertensive activities of bromocriptine.


clonidine may increase the hypertensive activities of ERGOTAMINE.


Arformoterol may increase the hypertensive activities of bromocriptine.


norepinephrine may increase the hypertensive activities of linezolid.


tetrahydrozoline may increase the hypertensive activities of pargyline.


clonidine may increase the hypertensive activities of methylergonovine.


methylphenidate may increase the hypertensive activities of pargyline.


hydroxyamphetamine may increase the hypertensive activities of tranylcypromine.


GUANFACINE may increase the hypertensive activities of cabergoline.


midodrine may increase the hypertensive activities of Tedizolid phosphate.


levonordefrin may increase the hypertensive activities of pargyline.


procarbazine may increase the hypertensive activities of Pirlindole.


procarbazine may increase the hypertensive activities of Toloxatone.


formoterol may increase the hypertensive activities of methylergonovine.


hydroxyamphetamine may increase the hypertensive activities of furazolidone.


AMPHETAMINE may increase the hypertensive activities of furazolidone.


ATROPINE may increase the hypertensive activities of Phenelzine.


droxidopa may increase the hypertensive activities of cabergoline.


methyldopa may increase the hypertensive activities of ERGOTAMINE.


dextroamphetamine may increase the hypertensive activities of Phenelzine.


hydroxyamphetamine may increase the hypertensive activities of Tedizolid phosphate.


midodrine may increase the hypertensive activities of Phenelzine.


methylphenidate may increase the hypertensive activities of isocarboxazid.


benzphetamine may increase the hypertensive activities of pargyline.


droxidopa may increase the hypertensive activities of Vilazodone.


phenylephrine may increase the hypertensive activities of moclobemide.


methoxamine may increase the hypertensive activities of linezolid.


methoxamine may increase the hypertensive activities of methylergonovine.


phenylpropanolamine may increase the hypertensive activities of ERGOTAMINE.


oxymetazoline may increase the hypertensive activities of linezolid.


methoxamine may increase the hypertensive activities of Atomoxetine.


phenylephrine may increase the hypertensive activities of dihydroergotamine.


phenylephrine may increase the hypertensive activities of cabergoline.


methylphenidate may increase the hypertensive activities of furazolidone.


dopamine may increase the hypertensive activities of Tedizolid phosphate.


norepinephrine may increase the hypertensive activities of Atomoxetine.


oxymetazoline may increase the hypertensive activities of ERGOTAMINE.


methylphenidate may increase the hypertensive activities of tranylcypromine.


dopamine may increase the hypertensive activities of Atomoxetine.


levonordefrin may increase the hypertensive activities of isocarboxazid.


dextroamphetamine may increase the hypertensive activities of Toloxatone.


metaraminol may increase the hypertensive activities of Tedizolid phosphate.


brimonidine may increase the hypertensive activities of ERGOTAMINE.


dextroamphetamine may increase the hypertensive activities of Pirlindole.


epinephrine may increase the hypertensive activities of linezolid.


apraclonidine may increase the hypertensive activities of dihydroergotamine.


methylphenidate may increase the hypertensive activities of AMPHETAMINE.


dobutamine may increase the hypertensive activities of methylergonovine.


terbutaline may increase the hypertensive activities of bromocriptine.


OLODATEROL may increase the hypertensive activities of dihydroergotamine.


methoxamine may increase the hypertensive activities of ERGOTAMINE.


PSEUDOEPHEDRINE may increase the hypertensive activities of rasagiline.


midodrine may increase the hypertensive activities of furazolidone.


apraclonidine may increase the hypertensive activities of cabergoline.


droxidopa may increase the hypertensive activities of ERGOTAMINE.


guanabenz may increase the hypertensive activities of bromocriptine.


metaproterenol may increase the hypertensive activities of Tedizolid phosphate.


midodrine may increase the hypertensive activities of dihydroergotamine.


norepinephrine may increase the hypertensive activities of Phenelzine.


epinephrine may increase the hypertensive activities of Atomoxetine.


phenylpropanolamine may increase the hypertensive activities of bromocriptine.


epinephrine may increase the hypertensive activities of dihydroergotamine.


phenylephrine may increase the hypertensive activities of tranylcypromine.


norepinephrine may increase the hypertensive activities of ERGOTAMINE.


ATROPINE may increase the hypertensive activities of tranylcypromine.


naphazoline may increase the hypertensive activities of dihydroergotamine.


phenylephrine may increase the hypertensive activities of furazolidone.


terbutaline may increase the hypertensive activities of cabergoline.


ATROPINE may increase the hypertensive activities of AMPHETAMINE.


ERGOTAMINE may increase the hypertensive activities of AMPHETAMINE.


Toloxatone may increase the hypertensive activities of Phenelzine.


clenbuterol may increase the hypertensive activities of Tedizolid phosphate.


ritodrine may increase the hypertensive activities of Tedizolid phosphate.


Amfepramone may increase the hypertensive activities of isocarboxazid.


Lisdexamfetamine may increase the hypertensive activities of isocarboxazid.


doxapram may increase the hypertensive activities of moclobemide.


terbutaline may increase the hypertensive activities of Atomoxetine.


ARBUTAMINE may increase the hypertensive activities of cabergoline.


Ephedrine may increase the hypertensive activities of Atomoxetine.


levonordefrin may increase the hypertensive activities of rasagiline.


methylphenidate may increase the hypertensive activities of moclobemide.


norepinephrine may increase the hypertensive activities of isocarboxazid.


hydroxyamphetamine may increase the hypertensive activities of pargyline.


nylidrin may increase the hypertensive activities of linezolid.


Amfepramone may increase the hypertensive activities of Phenelzine.


tetrahydrozoline may increase the hypertensive activities of furazolidone.


PROCATEROL may increase the hypertensive activities of Tedizolid phosphate.


ATROPINE may increase the hypertensive activities of Pirlindole.


ATROPINE may increase the hypertensive activities of Toloxatone.


acebutolol may increase the hypertensive activities of Atomoxetine.


doxapram may increase the hypertensive activities of tranylcypromine.


Dexmethylphenidate may increase the hypertensive activities of procarbazine.


isoxsuprine may increase the hypertensive activities of Tedizolid phosphate.


methylphenidate may increase the hypertensive activities of Phenelzine.


epinephrine may increase the hypertensive activities of moclobemide.


nitrous oxide may increase the hypertensive activities of methylphenidate.


midodrine may increase the hypertensive activities of pargyline.


levonordefrin may increase the hypertensive activities of AMPHETAMINE.


phenylpropanolamine may increase the hypertensive activities of linezolid.


labetalol may increase the hypertensive activities of linezolid.


hydroxyamphetamine may increase the hypertensive activities of isocarboxazid.


clonidine may increase the hypertensive activities of cabergoline.


MEPHENTERMINE may increase the hypertensive activities of ERGOTAMINE.


isoetharine may increase the hypertensive activities of methylergonovine.


Amfepramone may increase the hypertensive activities of Toloxatone.


isoproterenol may increase the hypertensive activities of methylergonovine.


nylidrin may increase the hypertensive activities of ERGOTAMINE.


METHAMPHETAMINE may increase the hypertensive activities of furazolidone.


methoxamine may increase the hypertensive activities of dihydroergotamine.


ritodrine may increase the hypertensive activities of bromocriptine.


Dexmethylphenidate may increase the hypertensive activities of Phenelzine.


Toloxatone may increase the hypertensive activities of Pirlindole.


DESFLURANE may increase the hypertensive activities of methylphenidate.


ATROPINE may increase the hypertensive activities of procarbazine.


midodrine may increase the hypertensive activities of ERGOTAMINE.


PSEUDOEPHEDRINE may increase the hypertensive activities of methylene blue.


tetrahydrozoline may increase the hypertensive activities of rasagiline.


epinephrine may increase the hypertensive activities of Toloxatone.


PSEUDOEPHEDRINE may increase the hypertensive activities of Pirlindole.


ATROPINE may increase the hypertensive activities of rasagiline.


Amfepramone may increase the hypertensive activities of Pirlindole.


Mirabegron may increase the hypertensive activities of bromocriptine.


methylphenidate may increase the hypertensive activities of methylene blue.


Amfepramone may increase the hypertensive activities of methylene blue.


epinephrine may increase the hypertensive activities of bromocriptine.


methylphenidate may increase the hypertensive activities of Pirlindole.


methylphenidate may increase the hypertensive activities of Toloxatone.


ritodrine may increase the hypertensive activities of cabergoline.


Pirlindole may increase the hypertensive activities of selegiline.


MEPHENTERMINE may increase the hypertensive activities of linezolid.


methoxamine may increase the hypertensive activities of procarbazine.


Amfepramone may increase the hypertensive activities of AMPHETAMINE.


ARBUTAMINE may increase the hypertensive activities of methylergonovine.


metaproterenol may increase the hypertensive activities of linezolid.


methoxamine may increase the hypertensive activities of rasagiline.


METHAMPHETAMINE may increase the hypertensive activities of Tedizolid phosphate.


norepinephrine may increase the hypertensive activities of dihydroergotamine.


doxapram may increase the hypertensive activities of selegiline.


metaproterenol may increase the hypertensive activities of Atomoxetine.


metaraminol may increase the hypertensive activities of cabergoline.


ARBUTAMINE may increase the hypertensive activities of dihydroergotamine.


methoxamine may increase the hypertensive activities of Tedizolid phosphate.


tetrahydrozoline may increase the hypertensive activities of selegiline.


PSEUDOEPHEDRINE may increase the hypertensive activities of pargyline.


benzphetamine may increase the hypertensive activities of tranylcypromine.


metaraminol may increase the hypertensive activities of procarbazine.


clenbuterol may increase the hypertensive activities of Atomoxetine.


norepinephrine may increase the hypertensive activities of Tedizolid phosphate.


doxapram may increase the hypertensive activities of pargyline.


Ephedrine may increase the hypertensive activities of linezolid.


isoxsuprine may increase the hypertensive activities of cabergoline.


MEPHENTERMINE may increase the hypertensive activities of bromocriptine.


METHAMPHETAMINE may increase the hypertensive activities of rasagiline.


PSEUDOEPHEDRINE may increase the hypertensive activities of bromocriptine.


Salbutamol may increase the hypertensive activities of dihydroergotamine.


celiprolol may increase the hypertensive activities of linezolid.


guanabenz may increase the hypertensive activities of methylergonovine.


Amfepramone may increase the hypertensive activities of moclobemide.


hydroxyamphetamine may increase the hypertensive activities of linezolid.


norepinephrine may increase the hypertensive activities of methylergonovine.


isoflurane may increase the hypertensive activities of methylphenidate.


hydroxyamphetamine may increase the hypertensive activities of rasagiline.


AMPHETAMINE may increase the hypertensive activities of linezolid.


ERGOTAMINE may increase the hypertensive activities of Pirlindole.


PROCATEROL may increase the hypertensive activities of ERGOTAMINE.


MEPHENTERMINE may increase the hypertensive activities of Tedizolid phosphate.


levonordefrin may increase the hypertensive activities of Pirlindole.


phenylephrine may increase the hypertensive activities of bromocriptine.


PROCATEROL may increase the hypertensive activities of Atomoxetine.


levonordefrin may increase the hypertensive activities of methylene blue.


PROCATEROL may increase the hypertensive activities of dihydroergotamine.


methoxamine may increase the hypertensive activities of furazolidone.


dobutamine may increase the hypertensive activities of linezolid.


OLODATEROL may increase the hypertensive activities of cabergoline.


doxapram may increase the hypertensive activities of rasagiline.


epinastine may increase the hypertensive activities of ERGOTAMINE.


enflurane may increase the hypertensive activities of methylphenidate.


guanabenz may increase the hypertensive activities of dihydroergotamine.


furazolidone may increase the hypertensive activities of Phenelzine.


dipivefrin may increase the hypertensive activities of bromocriptine.


phenylephrine may increase the hypertensive activities of Toloxatone.


phenylephrine may increase the hypertensive activities of Pirlindole.


phenylephrine may increase the hypertensive activities of methylene blue.


hydroxyamphetamine may increase the hypertensive activities of Atomoxetine.


PSEUDOEPHEDRINE may increase the hypertensive activities of dihydroergotamine.


PSEUDOEPHEDRINE may increase the hypertensive activities of Tedizolid phosphate.


dobutamine may increase the hypertensive activities of ERGOTAMINE.


metaraminol may increase the hypertensive activities of ERGOTAMINE.


benzphetamine may increase the hypertensive activities of Atomoxetine.


PSEUDOEPHEDRINE may increase the hypertensive activities of Atomoxetine.


epinephrine may increase the hypertensive activities of selegiline.


midodrine may increase the hypertensive activities of selegiline.


isoproterenol may increase the hypertensive activities of Tedizolid phosphate.


HEXOPRENALINE may increase the hypertensive activities of bromocriptine.


celiprolol may increase the hypertensive activities of Tedizolid phosphate.


tetrahydrozoline may increase the hypertensive activities of Tedizolid phosphate.


clenbuterol may increase the hypertensive activities of bromocriptine.


PIRBUTEROL may increase the hypertensive activities of methylergonovine.


OLODATEROL may increase the hypertensive activities of bromocriptine.


epinephrine may increase the hypertensive activities of furazolidone.


dobutamine may increase the hypertensive activities of dihydroergotamine.


dobutamine may increase the hypertensive activities of Atomoxetine.


phenmetrazine may increase the hypertensive activities of linezolid.


epinephrine may increase the hypertensive activities of pargyline.


metaraminol may increase the hypertensive activities of tranylcypromine.


terbutaline may increase the hypertensive activities of Tedizolid phosphate.


epinastine may increase the hypertensive activities of bromocriptine.


Lisdexamfetamine may increase the hypertensive activities of pargyline.


ATROPINE may increase the hypertensive activities of selegiline.


metaraminol may increase the hypertensive activities of Atomoxetine.


midodrine may increase the hypertensive activities of methylergonovine.


PIRBUTEROL may increase the hypertensive activities of ERGOTAMINE.


Dexmethylphenidate may increase the hypertensive activities of methylene blue.


AMPHETAMINE may increase the hypertensive activities of Phenelzine.


tetrahydrozoline may increase the hypertensive activities of moclobemide.


phenylephrine may increase the hypertensive activities of linezolid.


dipivefrin may increase the hypertensive activities of dihydroergotamine.


methoxamine may increase the hypertensive activities of selegiline.


dipivefrin may increase the hypertensive activities of ERGOTAMINE.


MEPHENTERMINE may increase the hypertensive activities of isocarboxazid.


norepinephrine may increase the hypertensive activities of tranylcypromine.


MEPHENTERMINE may increase the hypertensive activities of rasagiline.


isoxsuprine may increase the hypertensive activities of Atomoxetine.


isoxsuprine may increase the hypertensive activities of dihydroergotamine.


PSEUDOEPHEDRINE may increase the hypertensive activities of isocarboxazid.


norepinephrine may increase the hypertensive activities of furazolidone.


naphazoline may increase the hypertensive activities of cabergoline.


benzphetamine may increase the hypertensive activities of isocarboxazid.


phenylephrine may increase the hypertensive activities of ERGOTAMINE.


dipivefrin may increase the hypertensive activities of methylergonovine.


isoetharine may increase the hypertensive activities of bromocriptine.


Toloxatone may increase the hypertensive activities of selegiline.


METHAMPHETAMINE may increase the hypertensive activities of Atomoxetine.


epinephrine may increase the hypertensive activities of rasagiline.


OLODATEROL may increase the hypertensive activities of ERGOTAMINE.


Lofexidine may increase the hypertensive activities of methylergonovine.


epinephrine may increase the hypertensive activities of Pirlindole.


droxidopa may increase the hypertensive activities of midodrine.


droxidopa may increase the hypertensive activities of Eletriptan.


doxapram may increase the hypertensive activities of AMPHETAMINE.


epinephrine may increase the hypertensive activities of methylene blue.


MEPHENTERMINE may increase the hypertensive activities of methylergonovine.


phenylephrine may increase the hypertensive activities of isocarboxazid.


droxidopa may increase the hypertensive activities of pergolide.


norepinephrine may increase the hypertensive activities of pargyline.


METHAMPHETAMINE may increase the hypertensive activities of linezolid.


phenylephrine may increase the hypertensive activities of rasagiline.


hydroxyamphetamine may increase the hypertensive activities of Toloxatone.


hydroxyamphetamine may increase the hypertensive activities of Pirlindole.


hydroxyamphetamine may increase the hypertensive activities of methylene blue.


phenylpropanolamine may increase the hypertensive activities of methylergonovine.


Dexmethylphenidate may increase the hypertensive activities of moclobemide.


isoxsuprine may increase the hypertensive activities of linezolid.


naphazoline may increase the hypertensive activities of bromocriptine.


AMPHETAMINE may increase the hypertensive activities of Tedizolid phosphate.


Arformoterol may increase the hypertensive activities of methylergonovine.


tetrahydrozoline may increase the hypertensive activities of Phenelzine.


Pirlindole may increase the hypertensive activities of isocarboxazid.


AMPHETAMINE may increase the hypertensive activities of Atomoxetine.


phenylpropanolamine may increase the hypertensive activities of Tedizolid phosphate.


droxidopa may increase the hypertensive activities of apomorphine.


guanabenz may increase the hypertensive activities of cabergoline.


MEPHENTERMINE may increase the hypertensive activities of moclobemide.


Lofexidine may increase the hypertensive activities of dihydroergotamine.


metaraminol may increase the hypertensive activities of Toloxatone.


metaraminol may increase the hypertensive activities of Pirlindole.


Lisdexamfetamine may increase the hypertensive activities of tranylcypromine.


droxidopa may increase the hypertensive activities of ropinirole.


isoproterenol may increase the hypertensive activities of dihydroergotamine.


isoproterenol may increase the hypertensive activities of Atomoxetine.


HEXOPRENALINE may increase the hypertensive activities of dihydroergotamine.


droxidopa may increase the hypertensive activities of VORTIOXETINE.


AMPHETAMINE may increase the hypertensive activities of isocarboxazid.


HEXOPRENALINE may increase the hypertensive activities of methylergonovine.


AMPHETAMINE may increase the hypertensive activities of rasagiline.


methylphenidate may increase the hypertensive activities of selegiline.


tetrahydrozoline may increase the hypertensive activities of methylene blue.


acebutolol may increase the hypertensive activities of Tedizolid phosphate.


tetrahydrozoline may increase the hypertensive activities of linezolid.


tetrahydrozoline may increase the hypertensive activities of Toloxatone.


tetrahydrozoline may increase the hypertensive activities of Pirlindole.


methoxamine may increase the hypertensive activities of Phenelzine.


Lisdexamfetamine may increase the hypertensive activities of methylene blue.


ATROPINE may increase the hypertensive activities of moclobemide.


dextroamphetamine may increase the hypertensive activities of isocarboxazid.


Mirabegron may increase the hypertensive activities of cabergoline.


Ephedrine may increase the hypertensive activities of dihydroergotamine.


Salmeterol may increase the hypertensive activities of bromocriptine.


phenmetrazine may increase the hypertensive activities of Tedizolid phosphate.


naphazoline may increase the hypertensive activities of ERGOTAMINE.


hydroxyamphetamine may increase the hypertensive activities of moclobemide.


AMPHETAMINE may increase the hypertensive activities of Toloxatone.


dipivefrin may increase the hypertensive activities of cabergoline.


doxapram may increase the hypertensive activities of Pirlindole.


doxapram may increase the hypertensive activities of Toloxatone.


methoxamine may increase the hypertensive activities of moclobemide.


doxapram may increase the hypertensive activities of methylene blue.


PIRBUTEROL may increase the hypertensive activities of dihydroergotamine.


nylidrin may increase the hypertensive activities of methylergonovine.


epinephrine may increase the hypertensive activities of Phenelzine.


terbutaline may increase the hypertensive activities of ERGOTAMINE.


Toloxatone may increase the hypertensive activities of rasagiline.


Lisdexamfetamine may increase the hypertensive activities of rasagiline.


brimonidine may increase the hypertensive activities of cabergoline.


methyldopa may increase the hypertensive activities of methylergonovine.


nylidrin may increase the hypertensive activities of cabergoline.


nylidrin may increase the hypertensive activities of dihydroergotamine.


terbutaline may increase the hypertensive activities of dihydroergotamine.


oxymetazoline may increase the hypertensive activities of Atomoxetine.


Lisdexamfetamine may increase the hypertensive activities of Phenelzine.


tizanidine may increase the hypertensive activities of cabergoline.


oxymetazoline may increase the hypertensive activities of methylergonovine.


tizanidine may increase the hypertensive activities of dihydroergotamine.


droxidopa may increase the hypertensive activities of dihydroergotamine.


isoxsuprine may increase the hypertensive activities of methylergonovine.


PSEUDOEPHEDRINE may increase the hypertensive activities of Phenelzine.


benzphetamine may increase the hypertensive activities of furazolidone.


Dexmethylphenidate may increase the hypertensive activities of selegiline.


norepinephrine may increase the hypertensive activities of rasagiline.


PSEUDOEPHEDRINE may increase the hypertensive activities of furazolidone.


dopamine may increase the hypertensive activities of linezolid.


guanabenz may increase the hypertensive activities of ERGOTAMINE.


Amfepramone may increase the hypertensive activities of procarbazine.


Dexmethylphenidate may increase the hypertensive activities of furazolidone.


midodrine may increase the hypertensive activities of moclobemide.


Pirlindole may increase the hypertensive activities of rasagiline.


isoproterenol may increase the hypertensive activities of ERGOTAMINE.


epinastine may increase the hypertensive activities of cabergoline.


levonordefrin may increase the hypertensive activities of procarbazine.


Dexmethylphenidate may increase the hypertensive activities of pargyline.


benzphetamine may increase the hypertensive activities of Tedizolid phosphate.


metaraminol may increase the hypertensive activities of furazolidone.


midodrine may increase the hypertensive activities of linezolid.


Lofexidine may increase the hypertensive activities of cabergoline.


levonordefrin may increase the hypertensive activities of Phenelzine.


oxymetazoline may increase the hypertensive activities of dihydroergotamine.


PROCATEROL may increase the hypertensive activities of methylergonovine.


epinephrine may increase the hypertensive activities of isocarboxazid.


metaraminol may increase the hypertensive activities of pargyline.


HEXOPRENALINE may increase the hypertensive activities of cabergoline.


DEXMEDETOMIDINE may increase the hypertensive activities of cabergoline.


droxidopa may increase the hypertensive activities of sumatriptan.


methoxamine may increase the hypertensive activities of bromocriptine.


droxidopa may increase the hypertensive activities of LISURIDE.


methoxamine may increase the hypertensive activities of methylene blue.


formoterol may increase the hypertensive activities of cabergoline.


methoxamine may increase the hypertensive activities of Pirlindole.


methoxamine may increase the hypertensive activities of Toloxatone.


norepinephrine may increase the hypertensive activities of AMPHETAMINE.


Dexmethylphenidate may increase the hypertensive activities of rasagiline.


dextroamphetamine may increase the hypertensive activities of rasagiline.


isoproterenol may increase the hypertensive activities of linezolid.


isoproterenol may increase the hypertensive activities of bromocriptine.


formoterol may increase the hypertensive activities of dihydroergotamine.


tetrahydrozoline may increase the hypertensive activities of AMPHETAMINE.


metaraminol may increase the hypertensive activities of methylergonovine.


Dexmethylphenidate may increase the hypertensive activities of AMPHETAMINE.


midodrine may increase the hypertensive activities of Atomoxetine.


benzphetamine may increase the hypertensive activities of rasagiline.


methoxamine may increase the hypertensive activities of tranylcypromine.


Ephedrine may increase the hypertensive activities of Tedizolid phosphate.


GUANFACINE may increase the hypertensive activities of methylergonovine.


methoxamine may increase the hypertensive activities of cabergoline.


clenbuterol may increase the hypertensive activities of methylergonovine.


methoxyflurane may increase the hypertensive activities of methylphenidate.


midodrine may increase the hypertensive activities of methylene blue.


midodrine may increase the hypertensive activities of Pirlindole.


Amfepramone may increase the hypertensive activities of furazolidone.


Toloxatone may increase the hypertensive activities of isocarboxazid.


Mirabegron may increase the hypertensive activities of methylergonovine.


acebutolol may increase the hypertensive activities of linezolid.


metaproterenol may increase the hypertensive activities of bromocriptine.


epinephrine may increase the hypertensive activities of ERGOTAMINE.


phenylephrine may increase the hypertensive activities of methylergonovine.


epinephrine may increase the hypertensive activities of tranylcypromine.


norepinephrine may increase the hypertensive activities of Toloxatone.


norepinephrine may increase the hypertensive activities of Pirlindole.


norepinephrine may increase the hypertensive activities of methylene blue.


metaraminol may increase the hypertensive activities of isocarboxazid.


droxidopa may increase the hypertensive activities of Almotriptan.


METHAMPHETAMINE may increase the hypertensive activities of pargyline.


tetrahydrozoline may increase the hypertensive activities of procarbazine.


metaproterenol may increase the hypertensive activities of methylergonovine.


labetalol may increase the hypertensive activities of Atomoxetine.


phenylephrine may increase the hypertensive activities of Tedizolid phosphate.


tetrahydrozoline may increase the hypertensive activities of isocarboxazid.


MEPHENTERMINE may increase the hypertensive activities of Toloxatone.


MEPHENTERMINE may increase the hypertensive activities of Pirlindole.


droxidopa may increase the hypertensive activities of norepinephrine.


MEPHENTERMINE may increase the hypertensive activities of methylene blue.


norepinephrine may increase the hypertensive activities of selegiline.


apraclonidine may increase the hypertensive activities of methylergonovine.


PSEUDOEPHEDRINE may increase the hypertensive activities of methylergonovine.


ritodrine may increase the hypertensive activities of methylergonovine.


METHAMPHETAMINE may increase the hypertensive activities of isocarboxazid.


methyldopa may increase the hypertensive activities of dihydroergotamine.


Mirabegron may increase the hypertensive activities of ERGOTAMINE.


clenbuterol may increase the hypertensive activities of cabergoline.


Arformoterol may increase the hypertensive activities of ERGOTAMINE.


isoetharine may increase the hypertensive activities of dihydroergotamine.


DEXMEDETOMIDINE may increase the hypertensive activities of methylergonovine.


PSEUDOEPHEDRINE may increase the hypertensive activities of cabergoline.


ATROPINE may increase the hypertensive activities of isocarboxazid.


metaraminol may increase the hypertensive activities of methylene blue.


Lisdexamfetamine may increase the hypertensive activities of furazolidone.


metaproterenol may increase the hypertensive activities of dihydroergotamine.


benzphetamine may increase the hypertensive activities of methylene blue.


Toloxatone may increase the hypertensive activities of tranylcypromine.


midodrine may increase the hypertensive activities of rasagiline.


MEPHENTERMINE may increase the hypertensive activities of Atomoxetine.


benzphetamine may increase the hypertensive activities of Toloxatone.


benzphetamine may increase the hypertensive activities of Pirlindole.


metaproterenol may increase the hypertensive activities of ERGOTAMINE.


droxidopa may increase the hypertensive activities of zolmitriptan.


PSEUDOEPHEDRINE may increase the hypertensive activities of moclobemide.


midodrine may increase the hypertensive activities of bromocriptine.


DEXMEDETOMIDINE may increase the hypertensive activities of dihydroergotamine.


phenylpropanolamine may increase the hypertensive activities of Atomoxetine.


oxymetazoline may increase the hypertensive activities of cabergoline.


Amfepramone may increase the hypertensive activities of pargyline.


midodrine may increase the hypertensive activities of procarbazine.


PROCATEROL may increase the hypertensive activities of linezolid.


isoetharine may increase the hypertensive activities of cabergoline.


furazolidone may increase the hypertensive activities of tranylcypromine.


ERGOTAMINE may increase the hypertensive activities of Toloxatone.


Dexmethylphenidate may increase the hypertensive activities of isocarboxazid.


ERGOTAMINE may increase the hypertensive activities of methylene blue.


labetalol may increase the hypertensive activities of Tedizolid phosphate.


DEXMEDETOMIDINE may increase the hypertensive activities of ERGOTAMINE.


nylidrin may increase the hypertensive activities of Atomoxetine.


oxymetazoline may increase the hypertensive activities of Tedizolid phosphate.


phenylephrine may increase the hypertensive activities of procarbazine.


Pirlindole may increase the hypertensive activities of Phenelzine.


Salbutamol may increase the hypertensive activities of bromocriptine.


midodrine may increase the hypertensive activities of cabergoline.


ritodrine may increase the hypertensive activities of linezolid.


dobutamine may increase the hypertensive activities of bromocriptine.


PIRBUTEROL may increase the hypertensive activities of cabergoline.


furazolidone may increase the hypertensive activities of selegiline.


PSEUDOEPHEDRINE may increase the hypertensive activities of Toloxatone.


Salmeterol may increase the hypertensive activities of cabergoline.


norepinephrine may increase the hypertensive activities of procarbazine.


MEPHENTERMINE may increase the hypertensive activities of Phenelzine.


oxymetazoline may increase the hypertensive activities of bromocriptine.


ritodrine may increase the hypertensive activities of ERGOTAMINE.


dobutamine may increase the hypertensive activities of cabergoline.


metaraminol may increase the hypertensive activities of moclobemide.


celiprolol may increase the hypertensive activities of Atomoxetine.


midodrine may increase the hypertensive activities of Toloxatone.


methoxamine may increase the hypertensive activities of isocarboxazid.


doxapram may increase the hypertensive activities of Phenelzine.


metaraminol may increase the hypertensive activities of rasagiline.


clenbuterol may increase the hypertensive activities of linezolid.


METHAMPHETAMINE may increase the hypertensive activities of moclobemide.


epinephrine may increase the hypertensive activities of Tedizolid phosphate.


ATROPINE may increase the hypertensive activities of methylene blue.


furazolidone may increase the hypertensive activities of isocarboxazid.


Ephedrine may increase the hypertensive activities of ERGOTAMINE.


Dexmethylphenidate may increase the hypertensive activities of tranylcypromine.


benzphetamine may increase the hypertensive activities of moclobemide.


ritodrine may increase the hypertensive activities of dihydroergotamine.


ritodrine may increase the hypertensive activities of Atomoxetine.


levonordefrin may increase the hypertensive activities of Toloxatone.


norepinephrine may increase the hypertensive activities of moclobemide.


doxapram may increase the hypertensive activities of furazolidone.


PSEUDOEPHEDRINE may increase the hypertensive activities of ERGOTAMINE.


phenylephrine may increase the hypertensive activities of selegiline.


Amfepramone may increase the hypertensive activities of rasagiline.


TRICHLOROETHYLENE may increase the hypertensive activities of methylphenidate.


clenbuterol may increase the hypertensive activities of dihydroergotamine.


Ephedrine may increase the hypertensive activities of cabergoline.


ARBUTAMINE may increase the hypertensive activities of ERGOTAMINE.


MEPHENTERMINE may increase the hypertensive activities of pargyline.


terbutaline may increase the hypertensive activities of methylergonovine.


tobramycin may decrease the excretion rate of fenoprofen which could result in a higher serum level.


tobramycin may decrease the excretion rate of ketoprofen which could result in a higher serum level.


ribostamycin may decrease the excretion rate of oxaprozin which could result in a higher serum level.


Arbekacin may decrease the excretion rate of ETOFENAMATE which could result in a higher serum level.


daunorubicin may decrease the excretion rate of Apremilast which could result in a higher serum level.


Arbekacin may decrease the excretion rate of fenbufen which could result in a higher serum level.


amikacin may decrease the excretion rate of Icatibant which could result in a higher serum level.


Arbekacin may decrease the excretion rate of ADAPALENE which could result in a higher serum level.


metrizamide may decrease the excretion rate of mycophenolate mofetil which could result in a higher serum level.


plicamycin may decrease the excretion rate of Magnesium salicylate which could result in a higher serum level.


plicamycin may decrease the excretion rate of Salsalate which could result in a higher serum level.


paromomycin may decrease the excretion rate of Nepafenac which could result in a higher serum level.


daunorubicin may decrease the excretion rate of epirizole which could result in a higher serum level.


tobramycin may decrease the excretion rate of mycophenolate mofetil which could result in a higher serum level.


streptomycin may decrease the excretion rate of leflunomide which could result in a higher serum level.


netilmicin may decrease the excretion rate of aspirin which could result in a higher serum level.


Arbekacin may decrease the excretion rate of Masoprocol which could result in a higher serum level.


tobramycin may decrease the excretion rate of ETOFENAMATE which could result in a higher serum level.


tobramycin may decrease the excretion rate of fenbufen which could result in a higher serum level.


metrizamide may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.


streptozocin may decrease the excretion rate of carprofen which could result in a higher serum level.


metrizamide may decrease the excretion rate of ketorolac which could result in a higher serum level.


Valrubicin may decrease the excretion rate of nabumetone which could result in a higher serum level.


metrizamide may decrease the excretion rate of nabumetone which could result in a higher serum level.


Amfepramone may decrease the excretion rate of Almasilate which could result in a higher serum level.


Valrubicin may decrease the excretion rate of tenoxicam which could result in a higher serum level.


metrizamide may decrease the excretion rate of tenoxicam which could result in a higher serum level.


hydroxyamphetamine may decrease the excretion rate of Trometamol which could result in a higher serum level.


Valrubicin may decrease the excretion rate of mycophenolate mofetil which could result in a higher serum level.


ribostamycin may decrease the excretion rate of Pimecrolimus which could result in a higher serum level.


CALCIUM GLUCONATE may decrease the excretion rate of methyclothiazide which could result in a higher serum level.


ribostamycin may decrease the excretion rate of mycophenolate mofetil which could result in a higher serum level.


quinidine may decrease the excretion rate of Trometamol which could result in a higher serum level.


gentamicin may decrease the excretion rate of oxyphenbutazone which could result in a higher serum level.


Amfepramone may decrease the excretion rate of CALCIUM CARBONATE which could result in a higher serum level.


Amfepramone may decrease the excretion rate of Aluminium hydroxide which could result in a higher serum level.


ribostamycin may decrease the excretion rate of Etoricoxib which could result in a higher serum level.


ribostamycin may decrease the excretion rate of ketoprofen which could result in a higher serum level.


doxorubicin may decrease the excretion rate of PIRFENIDONE which could result in a higher serum level.


MEPHENTERMINE may decrease the excretion rate of SODIUM BICARBONATE which could result in a higher serum level.


streptozocin may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.


netilmicin may decrease the excretion rate of fenbufen which could result in a higher serum level.


plicamycin may decrease the excretion rate of meclofenamic acid which could result in a higher serum level.


netilmicin may decrease the excretion rate of ETOFENAMATE which could result in a higher serum level.


kanamycin may decrease the excretion rate of flurbiprofen which could result in a higher serum level.


plicamycin may decrease the excretion rate of salicylic acid which could result in a higher serum level.


Epirubicin may decrease the excretion rate of Olsalazine which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of mesalamine which could result in a higher serum level.


netilmicin may decrease the excretion rate of indomethacin which could result in a higher serum level.


Amfepramone may decrease the excretion rate of Bismuth subcitrate potassium which could result in a higher serum level.


netilmicin may decrease the excretion rate of CLONIXIN which could result in a higher serum level.


netilmicin may decrease the excretion rate of tolfenamic acid which could result in a higher serum level.


netilmicin may decrease the excretion rate of Droxicam which could result in a higher serum level.


netilmicin may decrease the excretion rate of Loxoprofen which could result in a higher serum level.


paromomycin may decrease the excretion rate of niflumic acid which could result in a higher serum level.


Epirubicin may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.


amikacin may decrease the excretion rate of suprofen which could result in a higher serum level.


ribostamycin may decrease the excretion rate of Apremilast which could result in a higher serum level.


streptomycin may decrease the excretion rate of Salsalate which could result in a higher serum level.


streptomycin may decrease the excretion rate of Magnesium salicylate which could result in a higher serum level.


Glubionate calcium may decrease the excretion rate of hydroflumethiazide which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of BENZYDAMINE which could result in a higher serum level.


streptozocin may decrease the excretion rate of Loxoprofen which could result in a higher serum level.


Arbekacin may decrease the excretion rate of oxaprozin which could result in a higher serum level.


streptozocin may decrease the excretion rate of Droxicam which could result in a higher serum level.


Valrubicin may decrease the excretion rate of fenbufen which could result in a higher serum level.


Valrubicin may decrease the excretion rate of ETOFENAMATE which could result in a higher serum level.


streptozocin may decrease the excretion rate of Lornoxicam which could result in a higher serum level.


doxorubicin may decrease the excretion rate of alclofenac which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of Masoprocol which could result in a higher serum level.


netilmicin may decrease the excretion rate of tolmetin which could result in a higher serum level.


tobramycin may decrease the excretion rate of ADAPALENE which could result in a higher serum level.


plicamycin may decrease the excretion rate of Masoprocol which could result in a higher serum level.


Arbekacin may decrease the excretion rate of ketoprofen which could result in a higher serum level.


Calcium phosphate may decrease the excretion rate of hydrochlorothiazide which could result in a higher serum level.


Epirubicin may decrease the excretion rate of indomethacin which could result in a higher serum level.


Amrubicin may decrease the excretion rate of ZILEUTON which could result in a higher serum level.


Amrubicin may decrease the excretion rate of etodolac which could result in a higher serum level.


gentamicin may decrease the excretion rate of diclofenac which could result in a higher serum level.


kanamycin may decrease the excretion rate of indomethacin which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of alclofenac which could result in a higher serum level.


metrizamide may decrease the excretion rate of diflunisal which could result in a higher serum level.


doxorubicin may decrease the excretion rate of oxyphenbutazone which could result in a higher serum level.


paromomycin may decrease the excretion rate of BENZYDAMINE which could result in a higher serum level.


Valrubicin may decrease the excretion rate of Olsalazine which could result in a higher serum level.


METHAMPHETAMINE may decrease the excretion rate of Bismuth subcitrate potassium which could result in a higher serum level.


kanamycin may decrease the excretion rate of ADAPALENE which could result in a higher serum level.


streptomycin may decrease the excretion rate of Naftifine which could result in a higher serum level.


Calcium citrate may decrease the excretion rate of BENDROFLUMETHIAZIDE which could result in a higher serum level.


Calcium phosphate may decrease the excretion rate of hydroflumethiazide which could result in a higher serum level.


gentamicin may decrease the excretion rate of Olopatadine which could result in a higher serum level.


Epirubicin may decrease the excretion rate of NAPROXEN which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of sulfasalazine which could result in a higher serum level.


Epirubicin may decrease the excretion rate of mefenamic acid which could result in a higher serum level.


paromomycin may decrease the excretion rate of PIRFENIDONE which could result in a higher serum level.


streptomycin may decrease the excretion rate of chloroquine which could result in a higher serum level.


daunorubicin may decrease the excretion rate of aspirin which could result in a higher serum level.


streptomycin may decrease the excretion rate of sulindac which could result in a higher serum level.


plicamycin may decrease the excretion rate of niflumic acid which could result in a higher serum level.


streptomycin may decrease the excretion rate of tiaprofenic acid which could result in a higher serum level.


doxorubicin may decrease the excretion rate of celecoxib which could result in a higher serum level.


Epirubicin may decrease the excretion rate of PIRFENIDONE which could result in a higher serum level.


daunorubicin may decrease the excretion rate of BALSALAZIDE which could result in a higher serum level.


plicamycin may decrease the excretion rate of PIRFENIDONE which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of salicylic acid which could result in a higher serum level.


Calcium citrate may decrease the excretion rate of methyclothiazide which could result in a higher serum level.


quinidine may decrease the excretion rate of Aluminium hydroxide which could result in a higher serum level.


plicamycin may decrease the excretion rate of BENZYDAMINE which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of meclofenamic acid which could result in a higher serum level.


plicamycin may decrease the excretion rate of leflunomide which could result in a higher serum level.


Amrubicin may decrease the excretion rate of antipyrine which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of Icatibant which could result in a higher serum level.


Arbekacin may decrease the excretion rate of floctafenine which could result in a higher serum level.


amikacin may decrease the excretion rate of tiaprofenic acid which could result in a higher serum level.


Amfepramone may decrease the excretion rate of SODIUM BICARBONATE which could result in a higher serum level.


metrizamide may decrease the excretion rate of mefenamic acid which could result in a higher serum level.


metrizamide may decrease the excretion rate of NAPROXEN which could result in a higher serum level.


streptozocin may decrease the excretion rate of tolmetin which could result in a higher serum level.


Amrubicin may decrease the excretion rate of Icatibant which could result in a higher serum level.


Arbekacin may decrease the excretion rate of epirizole which could result in a higher serum level.


Calcium acetate may decrease the excretion rate of trichlormethiazide which could result in a higher serum level.


amikacin may decrease the excretion rate of celecoxib which could result in a higher serum level.


metrizamide may decrease the excretion rate of meclofenamic acid which could result in a higher serum level.


paromomycin may decrease the excretion rate of mesalamine which could result in a higher serum level.


paromomycin may decrease the excretion rate of sulfasalazine which could result in a higher serum level.


doxorubicin may decrease the excretion rate of mesalamine which could result in a higher serum level.


amikacin may decrease the excretion rate of oxyphenbutazone which could result in a higher serum level.


hydroxyamphetamine may decrease the excretion rate of Magaldrate which could result in a higher serum level.


streptozocin may decrease the excretion rate of oxyphenbutazone which could result in a higher serum level.


doxorubicin may decrease the excretion rate of BENZYDAMINE which could result in a higher serum level.


Lisdexamfetamine may decrease the excretion rate of Bismuth subcitrate potassium which could result in a higher serum level.


tobramycin may decrease the excretion rate of Nepafenac which could result in a higher serum level.


Epirubicin may decrease the excretion rate of niflumic acid which could result in a higher serum level.


Valrubicin may decrease the excretion rate of ketorolac which could result in a higher serum level.


benzphetamine may decrease the excretion rate of methazolamide which could result in a higher serum level.


plicamycin may decrease the excretion rate of Nepafenac which could result in a higher serum level.


metrizamide may decrease the excretion rate of indomethacin which could result in a higher serum level.


amikacin may decrease the excretion rate of nimesulide which could result in a higher serum level.


tobramycin may decrease the excretion rate of ZILEUTON which could result in a higher serum level.


CALCIUM CHLORIDE may decrease the excretion rate of hydroflumethiazide which could result in a higher serum level.


tobramycin may decrease the excretion rate of etodolac which could result in a higher serum level.


Valrubicin may decrease the excretion rate of ADAPALENE which could result in a higher serum level.


ribostamycin may decrease the excretion rate of aspirin which could result in a higher serum level.


paromomycin may decrease the excretion rate of Pimecrolimus which could result in a higher serum level.


quinidine may decrease the excretion rate of dorzolamide which could result in a higher serum level.


Calcium phosphate may decrease the excretion rate of QUINETHAZONE which could result in a higher serum level.


ribostamycin may decrease the excretion rate of BALSALAZIDE which could result in a higher serum level.


netilmicin may decrease the excretion rate of epirizole which could result in a higher serum level.


AMPHETAMINE may decrease the excretion rate of Aluminium which could result in a higher serum level.


paromomycin may decrease the excretion rate of meclofenamic acid which could result in a higher serum level.


paromomycin may decrease the excretion rate of salicylic acid which could result in a higher serum level.


amikacin may decrease the excretion rate of alclofenac which could result in a higher serum level.


calcium lactate may decrease the excretion rate of hydroflumethiazide which could result in a higher serum level.


Valrubicin may decrease the excretion rate of tolmetin which could result in a higher serum level.


streptozocin may decrease the excretion rate of diclofenac which could result in a higher serum level.


streptozocin may decrease the excretion rate of ibuprofen which could result in a higher serum level.


Amrubicin may decrease the excretion rate of NAPROXEN which could result in a higher serum level.


amikacin may decrease the excretion rate of Aceclofenac which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of diclofenac which could result in a higher serum level.


Amrubicin may decrease the excretion rate of resveratrol which could result in a higher serum level.


PSEUDOEPHEDRINE may decrease the excretion rate of Aluminium which could result in a higher serum level.


PSEUDOEPHEDRINE may decrease the excretion rate of MAGNESIUM OXIDE which could result in a higher serum level.


amikacin may decrease the excretion rate of SERATRODAST which could result in a higher serum level.


plicamycin may decrease the excretion rate of resveratrol which could result in a higher serum level.


streptomycin may decrease the excretion rate of resveratrol which could result in a higher serum level.


amikacin may decrease the excretion rate of mesalamine which could result in a higher serum level.


cholic acid may decrease the excretion rate of Bosentan which could result in a higher serum level.


cholic acid may decrease the excretion rate of ketoconazole which could result in a higher serum level.


metrizamide may decrease the excretion rate of PIRFENIDONE which could result in a higher serum level.


netilmicin may decrease the excretion rate of Nepafenac which could result in a higher serum level.


gentamicin may decrease the excretion rate of Etoricoxib which could result in a higher serum level.


Arbekacin may decrease the excretion rate of BALSALAZIDE which could result in a higher serum level.


amikacin may decrease the excretion rate of acemetacin which could result in a higher serum level.


Arbekacin may decrease the excretion rate of ZILEUTON which could result in a higher serum level.


kanamycin may decrease the excretion rate of Pimecrolimus which could result in a higher serum level.


gentamicin may decrease the excretion rate of fenoprofen which could result in a higher serum level.


Valrubicin may decrease the excretion rate of Teriflunomide which could result in a higher serum level.


Arbekacin may decrease the excretion rate of etodolac which could result in a higher serum level.


gentamicin may decrease the excretion rate of azelastine which could result in a higher serum level.


daunorubicin may decrease the excretion rate of carprofen which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of aspirin which could result in a higher serum level.


tobramycin may decrease the excretion rate of flurbiprofen which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of Olopatadine which could result in a higher serum level.


MEPHENTERMINE may decrease the excretion rate of Magnesium trisilicate which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of Olopatadine which could result in a higher serum level.


Valrubicin may decrease the excretion rate of Propacetamol which could result in a higher serum level.


gentamicin may decrease the excretion rate of flurbiprofen which could result in a higher serum level.


kanamycin may decrease the excretion rate of ketoprofen which could result in a higher serum level.


gentamicin may decrease the excretion rate of celecoxib which could result in a higher serum level.


Epirubicin may decrease the excretion rate of sulfasalazine which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of NAPROXEN which could result in a higher serum level.


IDARUBICIN may decrease the excretion rate of mefenamic acid which could result in a higher serum level.


dextroamphetamine may decrease the excretion rate of Magaldrate which could result in a higher serum level.


Spectinomycin may decrease the excretion rate of oxyphenbutazone which could result in a higher serum level.


quinidine may decrease the excretion rate of Magaldrate which could result in a higher serum level.


gentamicin may decrease the excretion rate of Lumiracoxib which could result in a higher serum level.


metrizamide may decrease the excretion rate of alclofenac which could result in a higher serum level.


doxorubicin may decrease the excretion rate of suprofen which could result in a higher serum level.


paromomycin may decrease the excretion rate of ETOFENAMATE which could result in a higher serum level.


Amrubicin may decrease the excretion rate of Choline magnesium trisalicylate which could result in a higher serum level.


amikacin may decrease the excretion rate of sulindac which could result in a higher serum level.


plicamycin may decrease the excretion rate of flurbiprofen which could result in a higher serum level.


Amfepramone may decrease the excretion rate of methazolamide which could result in a higher serum level.